Pseudohypoparathyroidism medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 10: Line 10:
*The majority of cases of pseudohypoparathyroidism are self-limited and require only supportive care.
*The majority of cases of pseudohypoparathyroidism are self-limited and require only supportive care.
* The goal is to maintain serum [[calcium]] within the normal range to prevent [[hypercalciuria]] and to maintain [[parathyroid]] hormone levels within reference range which helps prevent bone remodeling and [[hyperparathyroid]] bone disease that can result from elevated [[parathyroid hormone]] level.
* The goal is to maintain serum [[calcium]] within the normal range to prevent [[hypercalciuria]] and to maintain [[parathyroid]] hormone levels within reference range which helps prevent bone remodeling and [[hyperparathyroid]] bone disease that can result from elevated [[parathyroid hormone]] level.
*Intravenous calcium is recommended for all patients who develop severe symptomatic [[hypocalcemia]]. Adult dosage is started 100 mg of elemental [[calcium]] (either [[calcium chloride]] or [[calcium gluconate]]) over 10 to 20 minutes. An additional dose of 100 mg/hr of [[elemental calcium]] can be infused if symptoms do not resolve, with close monitoring of [[calcium]] levels.Cardiac monitoring may help to guide therapy as rapid infusion of [[calcium]] can cause cardiac conduction defects;
*Intravenous calcium is recommended for all patients who develop severe symptomatic [[hypocalcemia]].  
*'''Adult'''
**Preferred regimen (1):elemental [[calcium]] (either [[calcium chloride]] or [[calcium gluconate]]) 100 mg of  over 10 to 20 minute
**An additional dose of 100 mg/hr of [[elemental calcium]] can be infused if symptoms do not resolve, with close monitoring of [[calcium]] levels
**Cardiac monitoring may help to guide therapy as rapid infusion of [[calcium]] can cause cardiac conduction defects;
* [[Parenteral|Parentera]]<nowiki/>l formulations available are [[calcium chloride]] and [[calcium gluconate]]; a 10-mL ampule of 10% [[calcium chloride]] contains 360 mg of [[elemental calcium]],and a 10-mL ampule of 10% [[calcium gluconate]] contains 93 mg of elemental [[calcium]].
* [[Parenteral|Parentera]]<nowiki/>l formulations available are [[calcium chloride]] and [[calcium gluconate]]; a 10-mL ampule of 10% [[calcium chloride]] contains 360 mg of [[elemental calcium]],and a 10-mL ampule of 10% [[calcium gluconate]] contains 93 mg of elemental [[calcium]].
*For [[neonates]], [[infants]], and [[children]], the recommended initial dose is 0.5-1 mL/kg of 10% [[calcium gluconate]] administered over 5 minutes.
*For [[neonates]], [[infants]], and [[children]], the recommended initial dose is 0.5-1 mL/kg of 10% [[calcium gluconate]] administered over 5 minutes.
Line 17: Line 21:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
[[Category:Disease]]

Revision as of 20:00, 29 September 2017

Pseudohypoparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pseudohypoparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pseudohypoparathyroidism medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pseudohypoparathyroidism medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pseudohypoparathyroidism medical therapy

CDC on Pseudohypoparathyroidism medical therapy

Pseudohypoparathyroidism medical therapy in the news

Blogs on Pseudohypoparathyroidism medical therapy

Directions to Hospitals Treating Pseudohypoparathyroidism

Risk calculators and risk factors for Pseudohypoparathyroidism medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

The mainstay of treatment for pseudohypoparathyroidism is oral calcium and 1alpha-hydroxylated vitamin D metabolites, such as calcitriol. Other forms of Vitamin D cannot be used as parathyroid hormone resistance in the proximal tubule decreases the efficiency of production of 1,25(OH)2 vitamin D from 25-hydroxyvitamin D.Intravenous calcium is recommended for all patients who develop severe symptomatic hypocalcemia.

Medical Therapy


References


Template:WikiDoc Sources